@article{oai:repo.qst.go.jp:00058564,
 author = {Kinuya, Seigo and Yoshinaga, Keiichiro and Higuchi, Tetsuya and Jinguji, Megumi and Kurihara, Hiroaki and Kawamoto, Hiroshi and 絹谷 清剛 and 吉永 恵一郎 and 樋口 徹也},
 issue = {1},
 journal = {The Japanese Journal of Nuclear Medicine},
 month = {Feb},
 note = {Since the 1980s when clinical therapeutic trials were initiated, 131I-MIBG radiotherapy has been used in foreign countries for unresectable neuroendocrine tumors including malignant pheochromocytomas and neuroblastomas. In Japan, 131I-MIBG radiotherapy has not been approved by the Ministry of Health, Labour and Welfare; however, personally imported 131I-MIBG is now available for therapeutic purposes in a limited number of institutions. These updated draft guidelines aim to provide useful information concerning 131I-MIBG radiotherapy, to prevent side effects, and to protect physicians, nurses, other health care professionals, patients and their families from radiation exposure. The committee has also provided appendices on topics such as practical guidance for attending physicians, patient management, and referring physicians.},
 pages = {1--48},
 title = {Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors},
 volume = {52},
 year = {2015}
}